Claudia Fish, MD
Endocrinology, Diabetes & Metabolism · Park City, UTNPI 1043293665
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $256,425 of the $286,370 with a category attached, or 89.5%. Lilly USA, LLC accounts for 82.9% of it on its own, with 29 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 729 payments — averaging $392.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$237K
- AstraZeneca$45K
- Novo Nordisk$707
- Amgen$613
- Chiesi USA, Inc.$346
- Sanofi-aventis U.S. LLC$267
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$256,42590%
- Travel & lodging$19,6777%
- Food & beverage$10,1914%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 480 | $237,451 |
| AstraZeneca(2 entities) | 71 | $44,871 |
| Novo Nordisk | 28 | $707 |
| Amgen(2 entities) | 26 | $613 |
| Chiesi USA, Inc. | 2 | $346 |
| Sanofi-aventis U.S. LLC | 16 | $267 |
| AbbVie | 8 | $252 |
| Pfizer | 11 | $216 |
| Merck | 11 | $170 |
| Medtronic(2 entities) | 7 | $133 |
| Dexcom, Inc. | 6 | $117 |
| Radius Health, Inc. | 6 | $115 |
| Amarin Pharma, Inc. | 5 | $113 |
| Insulet Corporation | 5 | $111 |
| Tandem Diabetes Care, Inc. | 6 | $108 |
| Ipsen Biopharmaceuticals, Inc | 5 | $101 |
| Mannkind Corporation | 4 | $101 |
| Abbott | 5 | $96 |
| Recordati_rare_diseases_inc. | 4 | $76 |
| Novartis | 4 | $72 |
| EUSA Pharma (US) LLC | 3 | $57 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Boehringer Ingelheim | 3 | $46 |
| Corcept Therapeutics | 3 | $43 |
| Madrigal Pharmaceuticals | 1 | $42 |
| Johnson & Johnson | 2 | $31 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Bayer | 1 | $13 |
| Lifescan, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$286,370 in reported general payments places this provider in the 95th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 182 | $321,185 |
| TrulicityDulaglutide | 199 | $319,124 |
| JardianceEmpagliflozin | 135 | $186,466 |
| OzempicSemaglutide | 82 | $161,911 |
| Teriparatide | 45 | $156,248 |
| FarxigaDapagliflozin Propanediol | 98 | $131,483 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 53 | $90,334 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $37,478 |
| Tresiba Flextouch U-100Insulin Degludec | 50 | $28,304 |
| JanuviaSitagliptin Phosphate | 19 | $27,409 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $19,976 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $16,622 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 23 | $14,151 |
| Novolog FlexpenInsulin Aspart | 50 | $12,150 |
| NovologInsulin Aspart | 26 | $12,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $237,451 | $644,455395 claims |
| Boehringer IngelheimJardiance | $46 | $186,466135 claims |
| Novo NordiskOzempic, Novolog | $707 | $173,915108 claims |
| AstraZenecaFarxiga | $44,871 | $131,48398 claims |
| MerckJanuvia | $170 | $27,40919 claims |
| AbbVieSynthroid | $252 | $3,17344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
Other endocrinology, diabetes & metabolism in Park City
- Eliot BrintonSalt Lake City$733K
- Alireza Falahati-NiniSalt Lake City$241K
- Steven BrownLayton$105K
- Timothy GrahamSandy$90K
- Jack WahlenOgden$70K
- Mohammed NizamProvo$54K
- Shahzad AhmadSalt Lake City$25K
- Priya KrishnamurthySt George$22K
- Vishnu SundareshSalt Lake City$18K
- David OkuboWest Jordan$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.